Five Tips To Removing Acne Scars

How to get rid of ugly acne scars? First, what are the acne scars? Acne skin is injured, and when the infection begins to heal, a cavity is left behind. The body feels faster cavities resulting in difficult skin discoloration, or scarring acne.

To remove the scars, use skin conditioners. The problem with most skin conditioners that leaves oily skin and can cause more acne. Some great ways to get rid of scars is by natural means. I'll give you five tips to help eliminate scars.

1. Aloe Vera Gel/Juice. This is really helpful when the wounds are fresh. Aloe Vera will help prevent scars from occurring.
2. Baking Soda: Baking soda is very good for the exfoliation of your skin. To use, mix one teaspoon of baking soda with two teaspoons of water. Rub on the affected area for about a minute, then rinse away.
3. Ice: Using ice cubes is very effective at removing scarring, but can be a little painful. Rub the ice on the scars for about fifteen minutes every day.
4. Egg Shells: This is similar to a process that professionals use called Dermabrasion. This process is expensive from a professional. You can get similar results by using egg shells. Boil the egg shells to sterilize them. Crush the egg shells into a gritty powder. Mix this with soap to form an excellent exfoliate for your skin.
5. Apples and Honey: This is a very popular method, because it will get rid of your scars and help prevent another acne breakout. When apples and honey are combined and placed on the skin, they will tighten your pores which will prevent dirt, germs and other material from accumulating in the pore. To create a mask of honey and apple, mash the flesh of an apple till a paste is formed. Add four or five drops of honey. Apply this to the affected skin, let dry, then rinse with cool water.

All of these are excellent ways to treat acne scars, and most of these will also treat acne, especially the last treatment mentioned. You should choose a skin care regiment and stick to it. Treat your skin by washing it, conditioning it, and applying your scar therapy at least twice a day. Be patient with these therapy's, they do take a little time to work, but you should see excellent results in a couple of days.

Skin Cancer and Alternative to Mohs Surgery

It is estimated that over 1 million new cases occur each year. It was also found that nearly half of all Americans living in 65 will develop skin cancer at least once. The two most common forms of skin cancer are basal cell carcinoma and squamous cell carcinoma. They represent about 96% of all skin cancers diagnosed. Together, these cancers also called non-melanoma skin.

Basal cell carcinoma is the most common form of skin cancer and accounts for more than 90% of all skin cancers in the SU These cancers almost never spread (metastasize) to other parts of the body . However, they can cause damage by growing and invading surrounding tissues. Squamous cell carcinoma is cancer that begins in squamous cells, which are thin, flat cells that look like fish scales under a microscope. Squamous cell carcinoma in the tissues that form the surface of the skin, the lining of hollow organs in the body and the passages of the respiratory and digestive tracts. Thus, squamous cell carcinoma is actually happening in any of these tissues. Squamous cell carcinoma of the skin occurs about one fourth as often as basal cell carcinoma.

A surgical method that is often used to treat skin cancer called non-melanoma Mohs surgery. This highly specialized surgical technique is to first remove the visible tumor and then successive layers of skin, one at a time until microscopic examination revealed no cancer cells. This surgery is performed while the patient is under local anesthesia. Remove and examine each layer takes about an hour, with a large proportion of this time looking at the skin removed. When finished, surgical wounds are treated as necessary. Treatment may include the closure of the wound with stitches covering the surgical site with skin from another area of ​​the body (skin graft), and moving healthy skin from a nearby area to cover the surgical wounds ( flap of skin).

Mohs surgery is the only way to successfully treat skin cancer? The surgery of the nose, ears, eyelids or lips may cause deformation or require reconstructive surgery under general anesthesia in order to maintain the natural appearance. Brachytherapy with Flexitron system is an effective alternative treatment for BCC (Basel cell carcinoma) and SCC (squamous cell) skin cancer and avoids the need for reconstructive surgery. It also has advantages over surgery for patients with many injuries, elderly patients or patients who would otherwise not work and the benefits of radiotherapy, because it requires shorter processing time and fewer side effects.

New Treatment of Advanced Metastatic Melanoma

Melanoma, a deadly skin cancer, continues to increase. In the United States in 2010, an estimated 68,130 new cases of invasive cancer and 46 770 in melanoma in situ. In the same year, an estimated 8,700 people die from this malignancy. Melanoma can be cured if detected early and can be surgically removed. When melanoma has spread to the lymph node (s) or when more than 4 mm, there is the chance of metastasis (spread to distant organs). Melanoma can spread to the following organs: lungs, liver, brain, bones, intestines, pancreas, adrenal, kidney, spleen, heart, and thyroid. Pet imaging tests such as CT and MRI of the brain may be performed to look for metastases. Most patients with metastatic melanoma die within one year. Level 2-year survival of only 10-20%. Current treatments include chemotherapy, which dacarbazine is the most commonly used. Over the last decade, many drugs and vaccines have been tested, without success. Then approved the drug is interleukin-2 in 1998, but is highly toxic that doctors rarely use it now. Neither it nor other approved drugs, dacarbazine, has clearly demonstrated better survival. This year, two new drugs are being introduced. The first drug is Yervoy (ipilimumab), which has been approved by the FDA in March 2011. The second agent is vemurafenib, has completed clinical trials and awaiting approval.

Yervoy is an antibody that blocks T-lymphocyte associated antigen 4 (CTLA-4). This blockage increases T-cell proliferation, which produces a more active immune system to attack melanoma cells. A recent clinical trial enrolled 502 patients with metastatic melanoma previously untreated. The patients were randomly assigned to dacarbazine chemotherapy plus Yervoy, or chemotherapy alone. Overall survival was significantly longer in the group receiving Yervoy plus dacarbazine compared in the group receiving dacarbazine (11.2 months versus 9.1 months). At one year, 47% of patients Yervoy life, compared with 36% in the chemotherapy alone group. In two years, 29% of patients Yervoy life, compared with 18% in the chemotherapy alone group. In three years, 21% of patients Yervoy life, compared with 12% in the chemotherapy alone group. Yervoy can result in severe immune-mediated adverse reactions due to T cell activation and proliferation. These immune-mediated side effects may involve multiple organ systems. The most common adverse reactions severe enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy. Yervoy cost $ 120,000 to complete the treatment program, consisting of four infusions given over a period of three months.

Two promising new drugs, vemurafenib, targeted mutations in the BRAF gene (serine / threonine-protein kinase B-Raf). Approximately 50% of melanoma cases have this mutation. The clinical trial enrolled 675 patients with previously untreated, metastatic melanoma with BRAF mutations. Patients were randomly assigned to receive either vemurafenib or dacarbazine. At six months, overall survival was 84% in the vemurafenib and 64% in the chemotherapy group. Common side effects associated with vemurafenib is joint pain, rash, fatigue, hair loss, squamous cell carcinoma, photosensitivity, nausea, and diarrhea. In the study, 38% of patients required dose modification due to toxic effects. The drug is being considered for approval by the FDA's future potential in melanoma patients. Price tag is unknown at this time.